Advanced solid tumor
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old, subject to signed informed consent, both male and female; 2. Malignant solid tumors confirmed by histopathology or cytopathology; 3. ECOG PS 0-2 points; 4. According to the Curative Effect Evaluation Standard for Solid Tumors Version 1.1 (RECIST V1.1), at least one measurable lesion; 5. The expected survival time is >= 12 weeks; 6. Volunteer to join the study, sign informed consent, have good compliance, and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who are at risk of using PD-1 inhibitors: 1) Patients with any active, known or suspected autoimmune diseases; 2) Those who are known to be allergic to recombinant humanized PD-1 monoclonal antibody drugs and their components; 3) Prepare or have received stem cell transplantation or organ transplantation in the past; 3. Other severe, acute or chronic medical diseases or laboratory abnormalities that the researcher judges may increase the risks associated with participating in the research, or may interfere with the interpretation of the research results; 4. The researcher judged that the compliance is poor, or there are other circumstances that make it unsuitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;AEs; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;SAEs;ORR; | — |
Countries
China
Contacts
Public ContactHu Xiaohua
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed